| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
BridgeBio Pharma, Inc.
13D/A
BBIO · 10806X102
|
4.7% |
8/17/2026
Event 8/13/2026
|
||||
| KKR Genetic Disorder L.P. | 4.2% | |||||
| KKR Genetic Disorder GP LLC | 4.2% | |||||
| KKR Group Partnership L.P. | 4.7% | |||||
| KKR Group Holdings Corp. | 4.7% | |||||
| KKR Group Co. Inc. | 4.7% | |||||
| KKR & Co. Inc. | 4.7% | |||||
| KKR Management LLP | 4.7% | |||||
| Henry R. Kravis | 4.7% | |||||
| George R. Roberts | 4.7% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.